Respiratory Tract Diseases: Clinical Trials

52,503 trials for Respiratory Tract Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28876 completed, 8593 unknown, 5081 recruiting, 3786 terminated. 14946 Not applicable, 10210 Phase 2, 5915 Phase 1, 5770 Phase 3, 3046 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable14946Completed 8239, Unknown 2579, Recruiting 1518, Terminated 792, Not yet recruiting 761, Withdrawn 474, Active not recruiting 417, Enrolling by invitation 115, Suspended 51
Phase 210210Completed 5127, Unknown 1343, Terminated 1290, Recruiting 1033, Withdrawn 521, Active not recruiting 474, Not yet recruiting 365, Suspended 36, Enrolling by invitation 21
Phase 15915Completed 3281, Terminated 727, Recruiting 634, Unknown 529, Active not recruiting 306, Withdrawn 257, Not yet recruiting 144, Suspended 28, Enrolling by invitation 9
Phase 35770Completed 3467, Unknown 689, Terminated 583, Recruiting 415, Withdrawn 239, Active not recruiting 220, Not yet recruiting 126, Suspended 19, Enrolling by invitation 12
Phase 43046Completed 1891, Unknown 457, Terminated 252, Recruiting 176, Withdrawn 115, Not yet recruiting 80, Active not recruiting 60, Suspended 9, Enrolling by invitation 6
Early Phase 1429Completed 178, Unknown 89, Recruiting 50, Terminated 40, Not yet recruiting 24, Withdrawn 24, Active not recruiting 14, Enrolling by invitation 5, Suspended 5

Follow Respiratory Tract Diseases: new trials by email Literature Review of Respiratory Tract Diseases trials Research Report on Respiratory Tract Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PAP Systems External Clinical Studies (ECS)
PAP System A (with Amalfi) then PAP System B (with CLA11), PAP System B (with CLA11) then PAP System A (with Amalfi) - Obstructive Sleep Apnea
Not applicableNot yet recruitingResMed302028-08-012026-04-24
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
Personalized ART, Non-personalized ART - Empty Nose Syndrome, Nasal Obstruction
Not applicableNot yet recruitingStanford University402028-07-012025-10-10
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS
AYURVEDA treatment protocol, Control(Citrizine 10mg) - Allergic Rhinitis (AR)
Not applicableNot yet recruitingAmrita Vishwa Vidyapeetham1042028-06-302026-06-04
Bubble CPAP Team-Based Care Strategy Feasibility Trial
bCPAP team-based care strategy - Pneumonia in Children
Not applicableNot yet recruitingYale University952028-04-012026-06-02
Adiposity Distribution in Acute Respiratory Failure
PEEP Titration Using Electrical Impedance Tomography (EIT), Body Positioning: Supine and Prone - Acute Hypoxemic Respiratory Failure, Obesity
Not applicableNot yet recruitingMaurizio F. Cereda, MD802028-01-012025-06-13
PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer
Individualized pre-operative physical exercise, Post-operative rehabilitation physical exercise, Respiratory physiotherapy Prehabilitation - Lung Cancer
Not applicableNot yet recruitingFranciscoVeraSerrano842028-01-012026-03-17
Chronic COUGH Management in Interstitial Lung DisEase
Non-pharmacological cough control therapy, Healthy lifestyle - Interstitial Lung Disease, Chronic Cough
Not applicableNot yet recruitingAveiro University602027-12-202025-01-20
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7)
Visible light exposure - Exposure to Man-made Visible Light
Not applicableNot yet recruitingUniversity of Bern502027-12-012026-01-14
A Personalized Voice Restoration Device for Patients With Laryngectomy
Surface Electromyography - Dysphonia, Aphonia
Not applicableNot yet recruitingWeill Medical College of Cornell University1002027-12-012026-06-16
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7)
Visible light exposure - Exposure to Man-made Visible Light
Not applicableNot yet recruitingUniversity of Bern502027-12-012026-01-14
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
Testing Settings of NovaResp's cMAP® Software During Home PAP Therapy
Dynamic cMAP, Direct cMAP - Obstructive Sleep Apnea
Not applicableNot yet recruitingNovaResp Technologies Inc502027-11-302026-10-27
Symptom Management to Improve Completion of Patient-reported Outcome Measures
Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management - Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm
Not applicableNot yet recruitingHenry Ford Health System782027-10-012026-07-29
Developing an Intervention to Optimize Virtual Care Adoption for COPD Management
VC-OPTIONS - Chronic Obstructive Pulmonary Disease
Not applicableNot yet recruitingVA Office of Research and Development402027-09-022026-09-29
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
MN-08 24 mg/day, MN-08 60 mg/day - Pulmonary Arterial Hypertension
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162027-09-012026-09-14
Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support
Remote Management, Remote Monitoring Only - COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD
Not applicableNot yet recruitingSir Run Run Shaw Hospital2362027-08-012026-08-06
Perceptions of Undergraduate Students and Teaching Staff on Online Teaching
Questionnaire - Covid19
SuspendedMisr International University92092027-07-152026-10-08
Optimizing Dysphagia Treatment Delivery in Acute Care: A Hybrid Efficacy Implementation Trial
Expiratory muscle strength training (EMST), Standard of Care Dysphagia Treatment, Intensive Dysphagia Treatment - Dysphagia, Critical Illness
Not applicableNot yet recruitingVanderbilt University Medical Center1202027-07-012026-10-14
RSV Vaccination to Reduce Recurrent AECOPD
RSV vaccination (Arexvy, GlaxoSmithKline) - COPD, RSV
Phase 4Not yet recruitingChinese University of Hong Kong3202027-07-012026-04-13
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
Cheung-Bearelly Aesthesiometer, Transnasal Laryngoscopy, Questionnaires - Presbylarynx, Aspiration
SuspendedUniversity of California, San Francisco5052027-06-302026-11-05

Showing 20 of 52503. Sign in to see all of them.

Narrower conditions

COVID-19 (7576)  ·  Carcinoma, Non-Small-Cell Lung (7106)  ·  Pulmonary Disease, Chronic Obstructive (5344)  ·  Lung Neoplasms (5277)  ·  Asthma (4476)  ·  Sleep Apnea, Obstructive (2173)  ·  Influenza, Human (2166)  ·  Cystic Fibrosis (1584)  ·  Pneumonia (1395)  ·  Respiratory Insufficiency (1348)  ·  Respiratory Distress Syndrome (1345)  ·  Small Cell Lung Carcinoma (1207)  ·  Lung Diseases (1159)  ·  Sleep Apnea Syndromes (1084)  ·  Neoplasms (1083)

Broader conditions

Lung Diseases (38956)  ·  Pathological Conditions, Signs and Symptoms (15196)  ·  Infections (15138)  ·  Respiratory Tract Infections (13980)  ·  Neoplasms by Site (12319)  ·  Respiratory Tract Neoplasms (11976)  ·  Neoplasms (11826)  ·  Thoracic Neoplasms (11726)  ·  Pathologic Processes (11524)  ·  Virus Diseases (10600)  ·  RNA Virus Infections (10591)  ·  Lung Diseases, Obstructive (10392)  ·  Pneumonia (8709)  ·  Respiration Disorders (8616)

Interventions

Carboplatin (1088)  ·  Cisplatin (856)  ·  Pemetrexed (748)  ·  pembrolizumab (601)  ·  Paclitaxel (583)  ·  Docetaxel (515)  ·  Blood Specimen Collection (442)  ·  Influenza Vaccines (440)  ·  Standard of Care (432)  ·  Radiotherapy (415)  ·  Gemcitabine (401)  ·  Sodium Chloride (349)  ·  Continuous Positive Airway Pressure (347)  ·  Erlotinib Hydrochloride (337)  ·  Nivolumab (329)

Sponsors

GlaxoSmithKline (1014)  ·  AstraZeneca (871)  ·  Assistance Publique - Hôpitaux de Paris (493)  ·  Boehringer Ingelheim (480)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (396)  ·  Pfizer (381)  ·  National Cancer Institute (NCI) (360)  ·  Novartis Pharmaceuticals (354)  ·  Assiut University (353)  ·  M.D. Anderson Cancer Center (264)  ·  Mayo Clinic (237)  ·  Merck Sharp & Dohme LLC (211)  ·  National Heart, Lung, and Blood Institute (NHLBI) (211)  ·  National Taiwan University Hospital (206)  ·  Massachusetts General Hospital (196)

Countries

United States (16739)  ·  China (5296)  ·  France (4797)  ·  United Kingdom (3619)  ·  Canada (3582)  ·  Germany (3218)  ·  Spain (2987)  ·  Italy (2784)  ·  Turkey (Türkiye) (1999)  ·  Belgium (1867)  ·  South Korea (1744)  ·  Netherlands (1703)  ·  Australia (1624)  ·  Poland (1504)  ·  Brazil (1473)

Results publications

PMID 34473343, PMID 36472162, PMID 37983082, PMID 33331662, PMID 35244208, PMID 33511633, PMID 35713300, PMID 31986264, PMID 32031570, PMID 32091533, PMID 32109013, PMID 32171076, PMID 33502773, PMID 34013969, PMID 36734509, PMID 37162745, PMID 27881132, PMID 36695483, PMID 37010196, PMID 37489818, PMID 37591523, PMID 26903337, PMID 34495549, PMID 34658014, PMID 35688625, PMID 32167524, PMID 32943047, PMID 10793162, PMID 12091180, PMID 23688302, PMID 33710614, PMID 35815359, PMID 39393433, PMID 42149813, PMID 32250385, PMID 34350582, PMID 37542951, PMID 22797452, PMID 25693014, PMID 31319851, PMID 31401903, PMID 32142651, PMID 32192578, PMID 17507545, PMID 25981908, PMID 29400693, PMID 32007143, PMID 32105632, PMID 32926419, PMID 33044747

NIH funding

2023 (299), 2018 (187), 2015 (179), 2017 (173), 2016 (165), 2019 (162), 2025 (150), 2014 (131), 2009 (129), 2008 (87), U10CA031946 (52), P30CA033572 (39), U10CA032102 (37), 2005 (29), P30CA012197 (28)